Biolytica aims to become the leading data platform for preventive healthcare and longevity. The start-up that is already generating 6-figure turnover has now secured funding totalling CHF 5.25m from the Maximon Longevity Co-Investment Fund.
Biolytica’s focus is its Biolytica NEXUS health data platform, a AI-driven analytics platform that aggregates, visualizes and analyzes data from genomics, blood and epigenetic biomarkers, as well as microbiome biomarkers, wearable devices, lifestyle data and more. This enables Biolytica to provide solutions for healthcare professionals such as preventive medicine institutions, longevity centers, personalized wellness clinics but also insurance companies and others to create hyper-personalized client health journeys, based on the latest science.
Maximon’s backing underscores the growing interest in and demand for longevity solutions backed by solid scientific research. As people around the world seek ways to extend their healthy lifespan, and the move from “sick-care” to “health-care” trends, Biolytica is poised to become a leader in this rapidly evolving field.